Tumor Detection and Diagnosis Based on Biomarker

A special issue of Biosensors (ISSN 2079-6374). This special issue belongs to the section "Biosensors and Healthcare".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 3983

Special Issue Editor


E-Mail Website
Guest Editor
Medical Science Building, School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China
Interests: chemicobiology; pharmacochemistry; multi-omics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Tumors are the second-largest cause of mortality in the world. The early detection and diagnosis of a tumor can effectively reduce its occurrence and fatality rate. Cancer biomarkers are molecules that are present in human blood, urine, or saliva as well as in other bodily fluids, tissues, and cells that are used to identify various tumors and to monitor tumor progression. The discovery of tumor biomarkers, namely nucleic acids, proteins, small-molecule metabolites, and microorganisms, can be applied to the detection, diagnosis, and prognosis of tumors because of their high sensitivity and specificity and non-invasive nature. Furthermore, the development of novel, simple, highly sensitive, and specific biomarker detection techniques is also significant for the use of biomarkers in tumor detection. Therefore, this new Special Issue focuses on the publication of scientific papers about tumor-related biomarkers as well as novel analytical methods and technologies for cancer detection.

We kindly invite the submission of original research and review articles about novel tumor biomarkers and biosensor technologies for tumor detection, diagnosis, prognosis, and monitoring. 

Prof. Dr. Yuyang Jiang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biosensors is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biosensors
  • tumor biomarker
  • tumor diagnosis
  • tumor prognosis
  • tumor monitoring
  • liquid biopsy
  • non-invasion

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 4045 KiB  
Article
Simple Isothermal and Label-Free Strategy for Colorectal Cancer Potential Biomarker miR-625-5p Detection
by Yifei Chen, Lizhen Ye, Hui Chen, Tingting Fan, Cheng Qiu, Yan Chen and Yuyang Jiang
Biosensors 2023, 13(1), 78; https://doi.org/10.3390/bios13010078 - 02 Jan 2023
Cited by 2 | Viewed by 1578
Abstract
miRNA is considered a novel biomarker for cancer diagnosis and due to its low level in vivo, the development of new detection methods for it has become a research hotspot in recent years. Here, we firstly found that miR-625-5p was significantly upregulated in [...] Read more.
miRNA is considered a novel biomarker for cancer diagnosis and due to its low level in vivo, the development of new detection methods for it has become a research hotspot in recent years. Here, we firstly found that miR-625-5p was significantly upregulated in colorectal cancer tissues by means of differential expression analysis of the dbDEMC database and clinical validation. Subsequently, it was found that miR-625-5p promoted cell proliferation and migration but inhibited apoptosis through phenotypic experiments; thus, we initially identified miR-625-5p as a potential biomarker for colorectal cancer. Moreover, in order to monitor slight changes in the miR-625-5p level, we developed a novel detection method for it based on strand displacement amplification (SDA). In this system, a hairpin was designed to recognize and pair with miR-625-5p, which was used as a primer to initiate SDA, and a large number of complementary DNAs were generated via cyclic amplification, followed by the addition of SYBR Gold to achieve quantitative analysis of miR-625-5p. Moreover, this method showed a good response to miR-625-5p with a detection limit of 8.6 pM and a dynamic range of 0.01 to 200 nM, and the specificity of it was verified using a set of other miRNAs as an interference. Finally, we set up different concentrations of biologic samples for detection to verify the practicability of the method. The results of this study indicate that this detection method has great potential in clinical diagnosis. Full article
(This article belongs to the Special Issue Tumor Detection and Diagnosis Based on Biomarker)
Show Figures

Figure 1

10 pages, 1288 KiB  
Article
Simple Detection of DNA Methyltransferase with an Integrated Padlock Probe
by Yuehua Wang, Yingli Han, Fangyu Zhou, Tingting Fan and Feng Liu
Biosensors 2022, 12(8), 569; https://doi.org/10.3390/bios12080569 - 26 Jul 2022
Cited by 3 | Viewed by 1809
Abstract
DNA methyltransferases (MTases) can be regarded as biomarkers, as demonstrated by many studies on genetic diseases. Many researchers have developed biosensors to detect the activity of DNA MTases, and nucleic acid amplification, which need other probe assistance, is often used to improve the [...] Read more.
DNA methyltransferases (MTases) can be regarded as biomarkers, as demonstrated by many studies on genetic diseases. Many researchers have developed biosensors to detect the activity of DNA MTases, and nucleic acid amplification, which need other probe assistance, is often used to improve the sensitivity of DNA MTases. However, there is no integrated probe that incorporates substrates and template and primer for detecting DNA MTases activity. Herein, we first designed a padlock probe (PP) to detect DNA MTases, which combines target detection with rolling circle amplification (RCA) without purification or other probe assistance. As the substrate of MTase, the PP was methylated and defended against HpaII, lambda exonuclease, and ExoI cleavage, as well as digestion, by adding MTase and the undestroyed PP started RCA. Thus, the fluorescent signal was capable of being rapidly detected after adding SYBRTM Gold to the RCA products. This method has a detection limit of approximately 0.0404 U/mL, and the linear range was 0.5–110 U/mL for M.SssI. Moreover, complex biological environment assays present prospects for possible application in intricacy environments. In addition, the designed detection system can also screen drugs or inhibitors for MTases. Full article
(This article belongs to the Special Issue Tumor Detection and Diagnosis Based on Biomarker)
Show Figures

Figure 1

Back to TopTop